Summary
The chronic effect of the calcium antagonist nitrendipine was investigated on blood pressure (BP), plasma aldosterone concentration (PAC), plasma renin activity (PRA), and serum potassium in six patients with primary aldosteronism, either due to an (unilateral) aldosterone-producing adenoma (APA;n=3; age, 44±4 years; PAC, 312±96 pg/ml; PRA, <0.1 ng/l·h; serum potassium, 2.8±0.3 mmol/l) or to bilateral idiopathic hyperaldosteronism (IHA;n=3; age, 49±1 years; PAC, 212±32 pg/ml; PRA, 0.1±0.1 ng/l·h; serum potassium, 3.3±0.2 mmol/l). After with-drawal of antihypertensive medications at least 3 weeks prior to the study, nitrendipine was given orally in a daily dosage of 40 to 60 mg. BP, PAC, PRA, and serum potassium were determined before (see data above) and after 4 weeks of nitrendipine therapy. After 4 weeks, BP was significantly reduced (178±10 to 165±6 mmHg systolic, 109±7 to 101±6 mmHg diastolic) in three patients with APA and in two with IHA. No significant changes of PAC, PRA, and serum potassium were observed in these patients. However, one patient with clinical characteristics of IHA and a long-term history of diuretic therapy showed a complete normalization of BP, PAC, PRA, and serum potassium, suggesting that the etiology of autonomous hyperaldosteronism in this patient might differ from typical primary aldosteronism. From these findings we conclude that calcium antagonists may be helpful in lowering BP in those patients with primary aldosteronism who develop intolerable side effects under treatment with spironolactone or trilostane. However, calcium antagonists do not normalize hormonal and electrolyte abnormalities in primary aldosteronism. Normalization of PAC, PRA, BP, and serum potassium after calcium channel blockade in some patients with clinical characteristics of IHA might point to a calcium-dependent subset of autonomous hyperaldosteronism, provisionally termed “diuretic-induced tertiary hyperaldosteronism.”
Similar content being viewed by others
Abbreviations
- BP:
-
Blood pressure
- PAC:
-
Plasma aldosterone concentration
- PRA:
-
Plasma renin activity
- IHA:
-
Idiopathic hyperaldosteronism
- APA:
-
Aldosterone-producing adenoma
- CT:
-
Computed tomography
- MRI:
-
Magnetic resonance imaging
References
Aguilera G, Catt KJ (1986) Participation of voltage-dependent calcium channels in the regulation of adrenal glomerulosa function by angiotensin II and potassium. Endocrinology 118:112–118
Auda SP, Brenan MF, Gill JR (1980) Evolution of the surgical management of primary aldosteronism. Ann Surg 191:1–7
Beevers DG, Brown JJ, Ferriss JB, Lever AF, Robertson IS, Tree M (1976) Renal abnormalities and vascular complications in primary aldosteronism. Evidence on tertiary hpyeraldosteronism. Q J Med 179:401–410
Carey RM, Sen S, Dolan LM, Malchoff CD, Bumpus M (1984) Idiopathic hyperaldosteronism: a possible role for aldosterone stimulating factor. N Engl J Med 311:94–100
Carpene G, Rocco S, Opocher G, Mantero F (1987) Acute and chronic effect of nifedipine in primary aldosteronism. Ricerca Scientifica ed Educazione Permanente [Suppl 58]: Abstract 78
Conn JW (1955) Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 43:6–17
Foster R, Lobo MV, Rasmussen H, Marusic ET (1981) Calcium: its role in the mechanism of action of angiotensin II and potassium in aldosterone production. Endocrinology 109:2196–2201
Fujita R, Aguilera G, Catt KJ (1979) The role of cyclic AMP in aldosterone production by isolated zona glomerulosa cells. J Biol Chem 254:8567–8572
Ganguly A, Dowdy AJ, Luetscher JA, Melada GA (1973) Anomalous postural response of plasma aldosterone concentration in patients with aldosterone-producing adenoma. J Clin Endocrinol Metab 36:401–403
Groth H, Stimpel M, Edmonds D, Mosca R, Vetter W (1985) Nitrendipin, ein neuer Kalziumantagonist, als Basistherapie bei essentieller Hypertonie. Schweiz Rundsch Med (PRAXIS) 74:503–506
Groth H, Vetter W, Stimpel M, Greminger P, Tenschert W, Klaiber E, Vetter H (1985) Adrenalectomy in primary aldosteronism: a long-term follow-up study. Cardiology 72 (Suppl 1):107–116
Haber E, Koerner T, Page LB, Kliman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29:1349–1355
Nadler JL, Hsueh W, Horton R (1985) Therapeutic effect of calcium channel blockade in primary aldosteronism. J Clin Endocrinol Metab 60:896–899
Reid IA, Ganong WF (1977) Control of aldosterone secretion. In: Genest J, Koiw E, Kuchel O (eds) Hypertension: pathophysiology and treatment. McCraw-Hill, New York, pp 265–281
Stimpel M, von zur Mühlen A (1986) Diagnose des primären Aldosteronismus. Dtsch med Wochenschr 111:1484–1486
Stimpel M, Dralle H, von zur Mühlen A (1986) Therapie des primären Aldosteronismus. Dtsch med Wochenschr 111:1487–1488
Stimpel M, Vetter H, Groth H, Neyses L, Siegenthaler W, Vetter W (1985) Trilostane in the treatment of primary aldosteronism (Abstract). Excerpta Medica, International Congress Series 652 (7th International Congress of Endocrinology):1535
Stimpel M, Vetter W, Groth H, Greminger P, Vetter H (1985) Captopril before and after spironolactone therapy in primary aldosteronism — pathogenetic and therapeutical aspects. Klin Wochenschr 63:361–363
Thibonnier M, Corvol P, Banzet O, Menard J (1982) Acute antihypertensive and hormonal effects of a calcium antagonist in essential hypertension. J Cardiovasc Pharmacol 4:335–339
Vetter W, Vetter H, Siegenthaler W (1973) Radioimmunoassay for aldosterone without chromatography. II. Determination of plasma aldosterone. Acta Endocrinol (Copenhagen) 74:558–565
Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HJ, Wellman H, Donohue JP (1979) Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 90:386–395
Winterberg B, Vetter W, Groth H, Greminger P, Vetter H (1985) Primary aldosteronism: treatment with trilostane. Cardiology 72 (Suppl 1):117–121
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stimpel, M., Ivens, K., Volkmann, H.P. et al. Therapeutic value of calcium antagonists in autonomous hyperaldosteronism. Klin Wochenschr 67, 248–252 (1989). https://doi.org/10.1007/BF01717327
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01717327